RxDoctor Payments Data

Julia Hoffner, PA

Physician Assistant · Greensburg, PANPI 1457063489

Payments from drug & device makers

$3,265in general payments, 2019–2025

Across 164 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$381
  • Alkermes, Inc.$350
  • Johnson & Johnson$329
  • Vanda Pharmaceuticals Inc.$281
  • Otsuka America Pharmaceutical, Inc.$206
  • plus $526 from 8 others

What the payments were for

  • Food & beverage$3,16297%
  • Education$1023%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,265 in reported general payments places this provider in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$6,730
Medicare patients
23
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole19$53,287
VraylarCariprazine Hcl46$51,685
Invega SustennaPaliperidone Palmitate15$44,315
RexultiBrexpiprazole17$26,337
Lurasidone Hcl38$8,962
Duloxetine Hcl120$2,944
Ziprasidone Hcl49$2,623
Aripiprazole80$2,590
Divalproex Sodium ErDivalproex Sodium66$2,462
Bupropion XlBupropion Hcl58$2,083
Trazodone Hcl144$1,997
Carbamazepine33$1,845
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine25$1,827
Clomipramine Hcl19$1,595
Buspirone Hcl116$1,490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$206$79,62436 claims
AbbVieVraylar$1,191$51,68546 claims
Johnson & JohnsonInvega Sustenna$329$44,31515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Greensburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →